Zepbound vs Mounjaro: Differences Explained

This article contains affiliate links. GLP01 (operated by SwipeClick LLC) may receive compensation when you visit third-party providers through our links.

Zepbound vs Mounjaro is a common comparison that confuses many people — and for good reason. Both medications contain the exact same active ingredient (tirzepatide) made by the same manufacturer (Eli Lilly), yet they're marketed as separate products. Understanding the differences between Zepbound and Mounjaro is essential for navigating prescriptions, insurance coverage, and costs. This guide breaks down everything you need to know.

The Key Difference: Same Drug, Different Approvals

The most important distinction between Zepbound and Mounjaro is their FDA-approved indication:

• Mounjaro — FDA-approved for type 2 diabetes management (May 2022)
• Zepbound — FDA-approved for chronic weight management in eligible adults (November 2023)

Both contain tirzepatide. Both are weekly subcutaneous injections. Both are manufactured by Eli Lilly. The difference is purely regulatory — which condition each medication is officially approved to treat.

Why Does This Matter?

The FDA approval indication directly affects:

1. Insurance coverage — Plans may cover one but not the other
2. Prescribing — Your provider writes the prescription for the specific indication
3. Pricing — While the medications themselves are similar, pricing and savings programs may differ
4. Availability — Supply situations may vary between the two

Side-by-Side Comparison

How They Work (Identically)

Both Zepbound and Mounjaro work through the same dual-agonist mechanism:

GLP-1 Receptor Activation

Tirzepatide activates GLP-1 receptors, which may reduce appetite, slow gastric emptying, and improve blood sugar regulation. This mechanism is shared with other GLP-1 medications like semaglutide.

GIP Receptor Activation

What makes tirzepatide unique is its additional activation of GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action may enhance metabolic effects beyond what GLP-1 activation alone provides, potentially influencing fat metabolism and insulin sensitivity.

Dosing: Same Schedule, Same Doses

The titration schedule is identical for both medications:

1. Weeks 1–4: 2.5 mg (starting dose)
2. Weeks 5–8: 5 mg
3. Weeks 9–12: 7.5 mg (if needed)
4. Weeks 13–16: 10 mg (if needed)
5. Weeks 17–20: 12.5 mg (if needed)
6. Week 21+: 15 mg (maximum dose, if needed)

Your provider determines the appropriate maintenance dose based on your response and tolerability. Not everyone needs to reach 15 mg.

Insurance and Cost: Where the Real Differences Lie

This is where the Zepbound vs Mounjaro distinction matters most practically.

Insurance Coverage

Mounjaro for diabetes:

• Generally has broader insurance coverage because type 2 diabetes treatment has well-established coverage mandates
• Most commercial insurance plans include at least one GLP-1 for diabetes on their formulary
• Medicare Part D plans often cover diabetes medications

Zepbound for weight loss:

• Insurance coverage for weight management medications remains more limited
• Some commercial plans cover Zepbound, but many still exclude anti-obesity medications
• Medicare has historically not covered weight loss medications, though this is evolving
• Prior authorization requirements may be more stringent

Out-of-Pocket Pricing

Without insurance, both medications cost approximately $1,000–$1,100 per month at retail. However, savings programs differ:

Mounjaro Savings:

• Eli Lilly Savings Card for commercially insured patients
• LillyDirect program for certain patients
• Patient assistance programs for qualifying individuals

Zepbound Savings:

• Separate Eli Lilly Savings Card program for Zepbound
• LillyDirect program
• Patient assistance programs with their own eligibility criteria

A Common Scenario

Some patients with type 2 diabetes who also want to lose weight may find it more practical to use Mounjaro (the diabetes-approved version) because their insurance covers it more readily. Since both medications are identical, the weight management benefits may still occur even when prescribed for the diabetes indication.

Side Effects: Identical Profile

Because Zepbound and Mounjaro contain the same active ingredient at the same doses, their side effect profiles are the same:

Common Side Effects

• Nausea (most common, often improves over time)
• Diarrhea
• Constipation
• Decreased appetite
• Vomiting
• Abdominal pain
• Injection site reactions

Serious Side Effects

• Pancreatitis (seek immediate medical attention for severe abdominal pain)
• Gallbladder disease
• Hypoglycemia (especially with other diabetes medications)
• Thyroid C-cell tumors (boxed warning based on animal studies)
• Severe allergic reactions
• Kidney problems

Clinical Trial Results

Mounjaro Trials (SURPASS Program — Diabetes Focus)

The SURPASS trials studied tirzepatide in type 2 diabetes patients, demonstrating:

• Significant HbA1c reductions across all doses
• Weight loss as a secondary outcome: approximately 12–25 lbs on average depending on dose
• Superior glucose control compared to several other diabetes medications

Zepbound Trials (SURMOUNT Program — Weight Loss Focus)

The SURMOUNT trials studied tirzepatide specifically for weight management:

• SURMOUNT-1: Average weight loss of approximately 15–21% depending on dose
• SURMOUNT-2 (with diabetes): Average weight loss of approximately 12.8–14.7%
• Among the highest average weight loss results for any anti-obesity medication

Which One Should You Ask About?

The answer depends on your specific situation:

You may be prescribed Mounjaro if:

• You have type 2 diabetes (with or without weight management goals)
• Your insurance covers Mounjaro but not Zepbound
• Your provider determines diabetes management is the primary indication

You may be prescribed Zepbound if:

• You want FDA-approved weight management medication
• You don't have type 2 diabetes
• Your insurance covers anti-obesity medications
• Your provider prescribes specifically for weight management

What Your Provider Considers

Your healthcare provider will evaluate:

• Your medical diagnoses and health history
• Insurance coverage for each medication
• The most appropriate clinical indication
• Cost considerations and available savings programs
• Any contraindications or potential drug interactions

Can You Switch Between Them?

Since Zepbound and Mounjaro contain the same active ingredient, switching between them is medically straightforward. However, there are practical considerations:

• Insurance implications: Switching from one to the other may require new prior authorization
• Pharmacy processing: The prescription will need to be rewritten for the new brand
• Savings card eligibility: Different savings programs may apply
• Supply considerations: Availability may differ between the two products

Always work with your healthcare provider before making any changes to your medication.

Frequently Asked Questions

Is Zepbound just Mounjaro for weight loss?

Essentially, yes. Zepbound and Mounjaro contain the identical active ingredient (tirzepatide) at the same doses. The difference is the FDA-approved indication: Zepbound is approved for weight management, while Mounjaro is approved for type 2 diabetes. They work the same way and have the same side effects.

Why did Eli Lilly create two separate products?

Separate products allow Eli Lilly to market each for its specific FDA-approved indication, set up distinct pricing and savings programs, and navigate the different insurance coverage landscapes for diabetes vs weight management medications. From a regulatory perspective, the FDA approval process requires separate applications for different indications.

Which is cheaper, Zepbound or Mounjaro?

The retail price is similar for both medications. However, the effective cost to you may differ based on insurance coverage. If your plan covers diabetes medications but not weight loss medications, Mounjaro may be more affordable (if prescribed for diabetes). Savings card programs and patient assistance may also differ between the two.

Can I use Mounjaro for weight loss if I don't have diabetes?

If a provider prescribes Mounjaro for weight loss in someone without type 2 diabetes, this would be considered off-label use. While legal, off-label prescribing may affect insurance coverage. Zepbound would be the FDA-approved option for non-diabetic weight management with tirzepatide.

Are there any differences in the injection pens?

The injection devices are very similar but not identical. Both are single-use, pre-filled pens designed for weekly subcutaneous injection. The labeling, packaging, and pen design may differ slightly, but the administration process is essentially the same.

Taking the Next Step

Whether Zepbound or Mounjaro is the right choice for you depends on your medical situation, insurance coverage, and treatment goals. The most important step is having an informed conversation with a healthcare provider who can evaluate your individual needs.

Ready to explore your options? Take our free eligibility quiz → to find out which GLP-1 medications may be appropriate for your situation. You can also connect with a licensed telehealth provider for a personalized evaluation and prescription guidance.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

GLP01 is operated by SwipeClick LLC, a marketing company — not a healthcare provider. Telehealth services and medication availability may vary by state.